7 results
To investigate the efficacy, safety, and pharmacokinetics of intravenous volasertib + subcutaneous low-dose cytarabine in patients * 65 years of age with previously untreated acute myeloid leukaemia, ineligible for intensive remission induction…
Primary Objectives(1) investigate the safety and tolerability of JNJ-54175446 after multiple consecutive dose administrations;(2) investigate the plasma pharmacokinetics of JNJ-54175446 following multiple dose administration in healthy male subjects…
Primary objective:-To investigate the safety and tolerability of JNJ-54175446 in subjects with major depressive disorder.Secondary objectives:-Investigate the effect of JNJ-54175446 versus placebo on total sleep deprivation-induced changes in…
The objective is to define the maximum tolerable dose (MTD) by evaluation of dose-limiting toxicity (DLT) of volasertib in paediatric leukaemia and solid tumours in the age group 2 to less than 12 and 12 to less than 18 years. A further objective is…
To investigate the efficacy, safety, and pharmacokinetics of volasertib in combination with low-dose cytarabine versus investigator*s choice of anti-leukemic treatment in patients with relapsed or refractory acute myeloid leukemia with no…
.
Main objective- to investigate the effect of alfacalcidol on the treatment of secondary hyperparathyroidism in patients after RYGB Secondary objectives: - to investigate bone turnover and changes in BMD in relation to secondary hyperparathyroidism…